Medicines and Healthcare products Regulatory Agency Propose Levy to Replace Department of Health Funding
The Medicines and Healthcare products Regulatory Agency (MHRA) has released its business plan for 2017 to 2018.
Pinsent Masons report that amongst the top ten priorities set out in the business plan was the aim to develop a proposed model for future regulation of medicines and medical devices in the UK, post Brexit which protects public health, facilitates innovation, and minimises burden on industry.
At the moment the regulation of devices by the MHRA is primarily funded through a service level agreement with the Department of Health (DH) with approximately 10% of its revenue from fees charged for services. It is proposed that a levy for vigilance from devices manufacturers should be introduced which would replace the majority of DH funding for this area.
However, this would require primary legislation which would be timely to acquire amid the general election and Brexit negotiations and so DH funding has been confirmed for 2017/18.
To read more about this, please click here.